See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
RV Invest's mission is to support innovations that improve patients' lives. The fund engages early and stands alongside founders and researchers to bring outstanding ideas to market, investing in highly differentiated technical solutions that can become future standards of care. RV Invest is a VC fund backed by the Vetter Pharma family office, focusing exclusively on biotech and medtech startups developing breakthrough therapeutic modalities — including cell reprogramming, epigenome editing, targeted cell depletion, and RNA-guided technologies — across oncology, rare diseases, and beyond.
Notable quotes
“Asgard's unique approach to cancer immunotherapy by using direct cell reprogramming has great potential to create personalized treatments at scale which could be used in many cancer indications. We've been impressed by the elegance of the technology and robustness of the scientific package generated by Asgard's team. We are delighted to be supporting Asgard's stellar team on the path of bringing the drug to patients and joining such a strong group of investors.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Diagonal Therapeutics | Series B | $125m | 2026-01-08 |
| Valink Therapeutics | Series A | $12m | 2025-10-20 |
| Akribion Therapeutics | Seed | $8m | 2025-02-04 |
| Alesta Therapeutics | Series A | $72m | 2025-01-08 |
| Arda Therapeutics | Series A | $43m | 2024-10-01 |
| Asgard Therapeutics | Series A | $33m | 2024-03-14 |
| Tune Therapeutics | Series B | $175m | — |
| Immusoft | Series A | — | — |
Frequent co-investors
Fit check
Is RV Invest a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit